他拉唑帕利单药治疗携带DDR-HRR改变的mCRPC:与疗效相关的基因组特征
TALAPRO-1研究探索了携带DDR-HRR改变的经治mCRPC患者接受他拉唑帕利单药治疗的基因组特征与疗效关系。gLOH高患者客观缓解率显著高于gLOH低患者(53.3% vs 12.0%,p=0.0017),TP53或PTEN改变与缓解率无显著相关。
要点
- gLOH高状态与他拉唑帕利单药治疗更优的客观缓解率相关。
- TP53或PTEN改变状态对客观缓解率无显著影响。
- ATM改变患者中合并PTEN改变者客观缓解率更高,但样本量小。
核心结论
- 在携带DDR-HRR改变的mCRPC患者中,高gLOH状态与他拉唑帕利单药治疗增强的缓解相关。
研究设计与样本
- TALAPRO-1研究评估他拉唑帕利单药治疗经重度治疗的携带DDR-HRR改变的mCRPC患者,采用肿瘤和唾液样本进行体细胞-胚系-合子性预测分析基因组改变。
- 回顾性分析探索基因改变来源、非DDR-HRR基因改变状态、肿瘤突变负荷和gLOH与抗肿瘤活性的关联,计算ORR和OS(95%CI采用Clopper-Pearson法,p值采用双侧Fisher精确检验)。
主要发现
- 常见非DDR-HRR改变基因包括TMPRSS2、TP53、PTEN、雄激素受体(AR)、MYC和SPOP。
- TP53改变者ORR为30.0%,无TP53改变者为28.6%;PTEN改变者ORR为34.5%,无PTEN改变者为26.8%。
- 在ATM改变肿瘤中,合并PTEN改变者ORR为2/4,无PTEN改变者为0/13(p=0.044)。
- gLOH高患者ORR显著高于gLOH低患者(53.3% vs 12.0%;p=0.0017)。
- gLOH高患者中位OS为23.7个月,gLOH低患者为18.7个月(HR 0.92,95%CI 0.52-1.64)。
关键数值与推荐
- gLOH高状态与更高的ORR相关(53.3% vs 12.0%;p=0.0017)。
- ATM改变肿瘤中合并PTEN改变者ORR更高(2/4 vs 0/13;p=0.044)。
临床怎么用
- 对于携带DDR-HRR改变的mCRPC患者,gLOH高状态可能有助于筛选从他拉唑帕利单药治疗中获益的人群。
- TP53或PTEN改变状态不宜单独作为他拉唑帕利单药疗效的预测标志物。
局限性
- 分析为回顾性,且亚组样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The impact of alterations beyond DNA damage response-homologous recombination repair (DDR-HRR) genes on outcomes with poly(ADP-ribose) polymerase inhibitor monotherapy remains unknown. This study aims to explore the impact of genomic features and co-occurring alterations on treatment outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) and DDR-HRR alterations in TALAPRO-1. METHODS: TALAPRO-1 evaluated talazoparib monotherapy in heavily pretreated patients with mCRPC and DDR-HRR alterations. We used tumor and saliva alteration results, and somatic-germline-zygosity prediction to assess genomic alterations. KEY FINDINGS AND LIMITATIONS: Associations between antitumor activity and gene alteration origin, selected non-DDR-HRR gene alteration status, tumor mutational burden, and genomic loss of heterozygosity (gLOH) were explored. Objective response rates (ORRs) and median overall survival (OS) with 95% confidence intervals (Clopper-Pearson method) and p values (two-sided Fisher's exact test) were calculated. Commonly altered non-DDR-HRR genes included TMPRSS2, TP53, PTEN, androgen receptor (AR), MYC, and SPOP. ORRs were 30.0% and 34.5% in men with TP53 and PTEN alterations, respectively, and 28.6% and 26.8% in men without TP53 or PTEN alterations, respectively. In tumors bearing ATM alterations, ORR was greater in those with (two of four) versus without PTEN alterations (zero of 13; p = 0.044). ORR was significantly higher for gLOH-high than for gLOH-low patients (53.3% vs 12.0%; p = 0.0017). The median OS for gLOH-high patients was 23.7 mo versus 18.7 mo for gLOH-low patients (hazard ratio 0.92, 95% confidence interval 0.52-1.64). Our analyses are retrospective and limited by small subgroup sizes. CONCLUSIONS AND CLINICAL IMPLICATIONS: In men with mCRPC, high gLOH status was associated with enhanced responses to talazoparib.
引用
- Fizazi K, de Bono JS, Laird AD, et al. Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to Therapy. Eur Urol Oncol. 2025. PMID: 41173779. doi:10.1016/j.euo.2025.09.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。